At a glance

ClinicalIndex Comparison Record

Phase 3Completed· 346 enrolled

Drug / intervention

Ga-68 labeled PSMA-11 PETdrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03353740

NCT03353740Phase 3Completed

Compare CT.gov

Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence

Thomas Hope·interventional·Posted Nov 27, 2017·Updated Oct 21, 2021

In Brief

A Phase 3 clinical trial evaluating Ga-68 labeled PSMA-11 PET for Prostate Cancer. Completed, enrolled 346 participants across 1 site.

Detailed Summary

The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsProstate Cancer

CountriesUnited States

Collaborators--

Timeline

Phase 3CompletedFinished

201820192020202120222023202420252026

Enrollment StartSep 2017

First PostedNov 2017

Primary CompletionSep 2020

TodayJul 2026

First PostedNov 27, 2017

Enrollment StartSep 20, 2017

Primary CompletionSep 1, 2020

TodayJul 2, 2026

Enrollment to primary: 2.9 yearsPosted 8.6 years ago

Interventions

Ga-68 labeled PSMA-11 PETdrug

Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.